It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Among patients with diabetes receiving PCI, novel antidiabetic agents, compared with standard treatment, may reduce risk for acute kidney injury.